Region:Global
Product Code:GDME0320EPD
Cardiac Valve Repairs-Medical Devices Pipeline Assessment, 2017
Summary
GlobalData's Medical Devices sector report, "Cardiac Valve Repairs-Medical Devices Pipeline Assessment, 2017" provides an overview of Cardiac Valve Repairs currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Valve Repairs pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Cardiac Valve Repairs under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Cardiac Valve Repairs and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Cardiac Valve Repairs under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Cardiac Valve Repairs Overview 11
3 Products under Development 12
3.1 Cardiac Valve Repairs-Pipeline Products by Stage of Development 12
3.2 Cardiac Valve Repairs-Pipeline Products by Segment 13
3.3 Cardiac Valve Repairs-Pipeline Products by Territory 14
3.4 Cardiac Valve Repairs-Pipeline Products by Regulatory Path 15
3.5 Cardiac Valve Repairs-Pipeline Products by Estimated Approval Date 16
3.6 Cardiac Valve Repairs-Ongoing Clinical Trials 17
4 Cardiac Valve Repairs-Pipeline Products under Development by Companies 18
4.1 Cardiac Valve Repairs Companies-Pipeline Products by Stage of Development 18
4.2 Cardiac Valve Repairs-Pipeline Products by Stage of Development 20
5 Cardiac Valve Repairs Companies and Product Overview 22
5.1 4tech Cardio Ireland Limited Company Overview 22
5.1.1 4tech Cardio Ireland Limited Pipeline Products & Ongoing Clinical Trials Overview 22
5.2 Admedus Ltd Company Overview 25
5.2.1 Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
5.3 Agamit Medical Ltd (Inactive) Company Overview 27
5.3.1 Agamit Medical Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 27
5.4 Ample Medical Inc Company Overview 28
5.4.1 Ample Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.5 Ancora Heart Inc Company Overview 29
5.5.1 Ancora Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.6 Arbor Surgical Technologies, Inc. Company Overview 32
5.6.1 Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
5.7 BioStable Science & Engineering, Inc. Company Overview 33
5.7.1 BioStable Science & Engineering, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 Cardiosolutions Inc Company Overview 34
5.8.1 Cardiosolutions Inc Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 Cardious, Inc. Company Overview 35
5.9.1 Cardious, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Children's Hospital Boston Company Overview 36
5.10.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 36
5.11 CollPlant Ltd. Company Overview 39
5.11.1 CollPlant Ltd. Pipeline Products & Ongoing Clinical Trials Overview 39
5.12 coramaze technologies GmbH Company Overview 40
5.12.1 coramaze technologies GmbH Pipeline Products & Ongoing Clinical Trials Overview 40
5.13 Coroneo Inc. Company Overview 41
5.13.1 Coroneo Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.14 CUBE SRL Company Overview 42
5.14.1 CUBE SRL Pipeline Products & Ongoing Clinical Trials Overview 42
5.15 Daidalos Solutions BV Company Overview 43
5.15.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 43
5.16 Edwards Lifesciences Corp Company Overview 45
5.16.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 45
5.17 Emory University Company Overview 49
5.17.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 49
5.18 Lartim Medical Ltd Company Overview 51
5.18.1 Lartim Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
5.19 Mardil Medical, Inc. Company Overview 52
5.19.1 Mardil Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
5.20 Mayo Clinic US Company Overview 54
5.20.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 54
5.21 Medtentia International Ltd Oy Company Overview 55
5.21.1 Medtentia International Ltd Oy Pipeline Products & Ongoing Clinical Trials Overview 55
5.22 MiCardia Corp Company Overview 57
5.22.1 MiCardia Corp Pipeline Products & Ongoing Clinical Trials Overview 57
5.23 Michigan Critical Care Consultants, Inc. Company Overview 60
5.23.1 Michigan Critical Care Consultants, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.24 Micro Interventional Devices, Inc. Company Overview 62
5.24.1 Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
5.25 Millipede LLC Company Overview 65
5.25.1 Millipede LLC Pipeline Products & Ongoing Clinical Trials Overview 65
5.26 Mitral Heal Company Overview 66
5.26.1 Mitral Heal Pipeline Products & Ongoing Clinical Trials Overview 66
5.27 Mitralix Ltd. Company Overview 67
5.27.1 Mitralix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 67
5.28 Mitre Medical Corp. (Inactive) Company Overview 68
5.28.1 Mitre Medical Corp. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 68
5.29 Neochord Inc Company Overview 70
5.29.1 Neochord Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.30 North Carolina State University Company Overview 74
5.30.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 74
5.31 Phoenix Cardiac Devices, Inc. Company Overview 75
5.31.1 Phoenix Cardiac Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.32 QuantumCor Inc. (Inactive) Company Overview 77
5.32.1 QuantumCor Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 77
5.33 Rambam Health Care Campus Company Overview 78
5.33.1 Rambam Health Care Campus Pipeline Products & Ongoing Clinical Trials Overview 78
5.34 ReCor Medical, Inc. Company Overview 79
5.34.1 ReCor Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 79
5.35 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 80
5.35.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 80
5.36 Symetis AG Company Overview 81
5.36.1 Symetis AG Pipeline Products & Ongoing Clinical Trials Overview 81
5.37 TransCardiac Therapeutics, LLC Company Overview 82
5.37.1 TransCardiac Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 82
5.38 Trinity College Dublin Company Overview 83
5.38.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 83
5.39 Valcare Medical Company Overview 84
5.39.1 Valcare Medical Pipeline Products & Ongoing Clinical Trials Overview 84
5.40 Valtech Cardio Ltd Company Overview 86
5.40.1 Valtech Cardio Ltd Pipeline Products & Ongoing Clinical Trials Overview 86
5.41 Viacor Inc Company Overview 94
5.41.1 Viacor Inc Pipeline Products & Ongoing Clinical Trials Overview 94
6 Cardiac Valve Repairs- Recent Developments 95
6.1 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device 95
6.2 Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion 95
6.3 Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million 96
6.4 Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million 96
6.5 Mar 15, 2017: Corindus Vascular Robotics Reports Fourth Quarter and Full Year 2016 Results 97
6.6 Mar 01, 2017: Micro Interventional Devices Announces Second Successful Tricuspid Annuloplasty Procedure Utilizing MIA, Minimally Invasive Annuloplasty Technology 98
6.7 Feb 23, 2017: AtCor Signs Local Health System Agreement 99
6.8 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 100
6.9 Feb 07, 2017: Dextera Surgical Reports Fiscal 2017 Second Quarter Financial Results 103
6.10 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 104
6.11 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 104
6.12 Jan 23, 2017: NeoChord Names J. Alex Martin Chairman of the Board 106
6.13 Jan 17, 2017: Corindus Vascular Robotics Announces Business Accomplishments for Fourth Quarter and Full Year 2016 and Updates 2017 Financial Guidance 107
6.14 Dec 19, 2016: Micro Interventional Devices Announces First in Human Success Utilizing MIA, Minimally Invasive Annuloplasty Technology 108
6.15 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 108
6.16 Dec 05, 2016: 4Tech appoints new president and CEO 110
6.17 Nov 26, 2016: Edwards Lifesciences Acquires Valtech Cardio 111
6.18 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 111
6.19 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 114
6.20 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 115
6.21 Nov 09, 2016: First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation 116
6.22 Nov 08, 2016: Corindus Vascular Robotics Reports Third Quarter 2016 Results 117
6.23 Nov 07, 2016: Dextera Surgical Reports Fiscal 2017 First Quarter Financial Results 118
6.24 Oct 31, 2016: Guided Delivery Systems Announces Senior Leaders and Company Name Change to Ancora Heart 119
6.25 Oct 28, 2016: NeoChord Passes 500 Patient Treatment Milestone 120
6.26 Oct 28, 2016: 4Tech Elects Ex-Medtronic CEO William (“Bill”) A. Hawkins as its Chairman 121
6.27 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 122
6.28 Oct 20, 2016: Corindus Vascular Robotics Appoints Jeff Lemaster Chief Commercial Officer 123
6.29 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 124
6.30 Oct 17, 2016: Clinical study results reveal improved heart condition with Medtentia Annuloplasty Ring (MAR) 125
6.31 Oct 11, 2016: BioStable Science & Engineering Completes Direct De Novo Application to FDA for the HAART 300 Aortic Annuloplasty Device 126
6.32 Sep 27, 2016: Hannu Syrjala Appointed as New Chairman for Medtentia’s Board of Directors 127
6.33 Sep 16, 2016: World’s first Transcatheter Tricuspid Valve Repair (TTVR) has been successfully achieved without use of TEE and General Anesthesia in feasibility study of 4Tech TriCinch at San Raffaele Hospital, Milan, Italy 127
6.34 Sep 16, 2016: Valtech Cardio Presents: Cardioband Tricuspid Successful First in Man Cases and 2-Year Cardioband Mitral Data at PCR London Valves 2016 128
6.35 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 129
6.36 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 130
6.37 Aug 22, 2016: Data collection completed for the clinical study evaluating Medtentia Annuloplasty Ring safety and performance 132
6.38 Aug 09, 2016: Dextera Surgical Reports FY 2016 Fourth Quarter Financial Results 133
6.39 Aug 04, 2016: Corindus Vascular Robotics Reports Second Quarter 2016 Results 134
6.40 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results 135
6.41 Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results 137
6.42 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 139
6.43 Jun 29, 2016: Dextera Surgical Appoints Mark Soberman M.D., Leader in Thoracic Surgery, as Medical Director 139
6.44 Jun 20, 2016: Valcare Medical, an Accelmed Portfolio Company, Announces Successful First-In-Human Procedures of the Amend Catheter Delivered Annuloplasty Ring 140
6.45 Jun 20, 2016: Cardica Changes Company Name to Dextera Surgical 141
6.46 Jun 15, 2016: Transcatheter Tricuspid Valve Repair (TTVR) Has Been Successfully Achieved in Feasibility Study of 4Tech TriCinch at San Raffaele Hospital, Milan, Italy 141
6.47 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 142
6.48 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 143
6.49 May 16, 2016: BioStable Science & Engineering Initiates European Commercialization of the HAART 300 Aortic Annuloplasty Device 146
6.50 May 16, 2016: 4Tech and Dr. Jean-Claude Laborde enter into partnership to accelerate 4Tech R&D and clinical development 146
6.51 May 16, 2016: Otsuka Invests in ReCor Medical 147
6.52 May 13, 2016: NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation 147
6.53 May 12, 2016: ReCor Medical Raises USD10 Million in Venture Financing 148
6.54 Apr 19, 2016: Medtentia’s Board of Directors elected 148
6.55 Apr 08, 2016: Admedus Expands Distribution Agreement With Coroneo 148
6.56 Apr 08, 2016: Admedus Extends Distribution Agreement with Coroneo 149
7 Appendix 150
7.1 Methodology 150
7.2 About GlobalData 153
7.3 Contact Us 153
7.4 Disclaimer 153
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.